Search Results
Jun 07, 2026, 21:00 ET バイブコーディングの先へ：エージェント型AIが挑む大規模システム開発
Spec Driven for Enterpriseの中核を担うのが、エンタープライズシステム開発に必要な情報を統合・分析するナレッジファウンデーションです。このオントロジーデータベースは、開発標準、セキュリティポリシー、システムソースコード、開発成果物など、エンタープライズシステムに関する知識をAIが理解できる形式で構造化します。ナレッジファンデーションを基盤とするCline Spec Driven for Enterpriseは、組織のシステムや業務運用を学習し、カスタマイズされた開発を実現します。また、この基盤により、Cline Spec Driven for Enterpris
More news about: LG CNS
Jun 07, 2026, 21:00 ET Anamana Incubator Targets Culturally Native Creators to Diversify Homogenized Micro-Drama Market
outcomes — for the creator as well as Anamana as a platform — in emotionally resonant stories fundamentally built on a deep cultural insight only a creator who is also a cultural insider can have."The Anamana 100 Creator Incubator framework acts as a commercial co-investment partner for the entrepreneurial
More news about: Anamana
Jun 07, 2026, 21:00 ET Uhale Adopts Quokka's Q-mast to Strengthen Application Security Testing
regular development cycle.About UhaleUhale is a software provider for digital photo frames. It offers intuitive mobile apps and platform solutions for seamless photo sharing and management. Built for simplicity and flexibility, Uhale helps you connect with family and friends through
More news about: Uhale
Jun 07, 2026, 21:00 ET GIGABYTE Advances Gaming Monitor Technologies with AI-optimized Visuals and Automatic OLED Protection
settings for SDR content to improve overall visual presentation, automatically optimizing display settings based on different content types and usage scenarios without requiring frequent manual adjustments. While HyperNits dynamically enhances HDR brightness while preserving highlight detail for improved
More news about: GIGABYTE
Jun 07, 2026, 21:00 ET GIGABYTE Advances Gaming Monitor Technologies with AI-optimized Visuals and Automatic OLED Protection
settings for SDR content to improve overall visual presentation, automatically optimizing display settings based on different content types and usage scenarios without requiring frequent manual adjustments. While HyperNits dynamically enhances HDR brightness while preserving highlight detail for improved
More news about: GIGABYTE
Jun 07, 2026, 20:10 ET Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39
ASC39In vitro studies demonstrated that ASC39 exhibited selectivity for the human amylin type 1 receptor (hAMY1R) comparable to that of eloralintide, with substantially greater affinity for the amylin receptor than for the human calcitonin receptor (hCTR). This receptor selectivity may help minimize
More news about: Ascletis Pharma Inc.
Jun 07, 2026, 20:08 ET OriCell's GPC3 CAR-T Receives NMPA Clearance for Confirmatory Phase II Trial in Late-Line Advanced Hepatocellular Carcinoma
alone accounting for roughly 410,000 new cases and 317,000 deaths each year. For patients whose disease has progressed through both immune checkpoint inhibitors (ICI) and tyrosine kinase inhibitors (TKI), options are essentially exhausted: existing second-line agents were developed for patients intolerant
More news about: Oricell Therapeutics Holdings Limited
Jun 07, 2026, 20:00 ET Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance
targeting CD19 x CD3 (ATG-201 for B cell-related autoimmune diseases; partnered with UCB), CDH6 x CD3 (ATG-106 for ovarian cancer and kidney cancer), ALPPL2 x CD3 (ATG-112 for gynecological tumors, digestive system malignancies, bladder cancer and NSCLC), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal
More news about: Antengene Corporation Limited
Jun 07, 2026, 20:00 ET UPST Deadline: UPST Investors Have Opportunity to Lead Upstart Holdings, Inc. Securities Fraud Lawsuit
Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner
More news about: THE ROSEN LAW FIRM, P. A.
Jun 07, 2026, 18:52 ET Sportradar Group AG (SRAD) Investors: July 17, 2026, Deadline in Securities Fraud Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP
plaintiff by July 17, 2026.Contact KTMC for a free case evaluation. All representation is on a contingency fee basis, there is no cost to you.Retain counsel of choice or take no action.THE LEAD PLAINTIFF PROCESS FOR SPORTRADAR GROUP AG INVESTORS:Sportradar
More news about: Kessler Topaz Meltzer & Check, LLP
Jun 07, 2026, 18:30 ET VolitionRx Announces Pricing of $4.6 Million Public Offering
both new and existing investors. Maxim Group LLC is acting as the sole placement agent in connection with the offering.The gross proceeds for the offering are expected to be approximately $4.6 million before deducting placement agent fees and other offering expenses and excluding the proceeds
More news about: VolitionRx Limited
Jun 07, 2026, 18:13 ET FSK Investors Have Opportunity to Lead FS KKR Capital Corp. Securities Fraud Lawsuit
Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner
More news about: THE ROSEN LAW FIRM, P. A.
Jun 07, 2026, 17:30 ET Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications
emerging as therapeutic target for diabetes and obesity. Amylin helps balance blood glucose levels and makes people feel full after eating. Amylin agonists—synthetic versions that mimic the effects of the natural hormone—are a newer class of drugs. As the need for solutions for both weight loss and type 2
More news about: American Diabetes Association
Jun 07, 2026, 17:30 ET Novo Nordisk's CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026
CagriSemaOnce-weekly subcutaneous CagriSema is being investigated by Novo Nordisk as a treatment for adults with overweight or obesity (REDEFINE program) and as a treatment for adults with type 2 diabetes (REIMAGINE program). CagriSema is a fixed-dose combination of a long-acting amylin
More news about: NOVO NORDISK INC.
Jun 07, 2026, 16:45 ET AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial
More news about: Amgen
Jun 07, 2026, 16:45 ET Lipid-Lowering Medications Demonstrate Cardiometabolic Benefits in Populations with High-Risk Diabetes
likely to develop heart disease or stroke. This underscores the need to target risk factors for these conditions, including harmful triglycerides (a type of fat carried in your blood that your body uses for energy) and atherosclerosis (plaque buildup in the arteries that can cause heart disease), often
More news about: American Diabetes Association
Jun 07, 2026, 14:30 ET Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health
risk of MASH."There is a critical need for treatments that also drive meaningful improvements in overall metabolic health, and these findings are encouraging for potential new solutions," said Carel le Roux, MD, PhD, lead author of the study. "For patients, improving metabolic health is about
More news about: American Diabetes Association
Jun 07, 2026, 14:30 ET Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide
Ecnoglutide is a cAMP-biased GLP-1 receptor agonist developed by Sciwind Biosciences for obesity and related metabolic diseases. Pfizer has exclusive commercialization rights for Sciwind's injectible ecnoglutide product in Mainland China.About Sciwind BiosciencesSciwind
More news about: Sciwind Biosciences Co., Ltd.
Jun 07, 2026, 13:24 ET Rosen Law Firm Encourages DNOW Inc. Investors to Inquire About Securities Class Action Investigation - DNOW
Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner
More news about: THE ROSEN LAW FIRM, P. A.
Jun 07, 2026, 12:00 ET Bronstein, Gewirtz & Grossman LLC Urges Badger Meter, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Company possessed a "long runway" for growth, the Company's growth prospects were materially overstated, such that Defendants lacked a reasonable basis for their positive statements about the Company's business, operations, and future prospects.What's Next for Badger Meter Investors?A
More news about: Bronstein, Gewirtz & Grossman, LLC
Jun 07, 2026, 12:00 ET Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm
contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.Why Bronstein, Gewirtz & Grossman, LLC for GeneDx Securities Class Action?Bronstein, Gewirtz &
More news about: Bronstein, Gewirtz & Grossman, LLC
Jun 07, 2026, 11:00 ET Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
help you decide if Zepbound is right for you.ZP CON BS 25FEB2026About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines
More news about: Eli Lilly and Company
Jun 07, 2026, 10:40 ET RGC Deadline: RGC Investors with Losses in Excess of $100K Have Opportunity to Lead Regencell Bioscience Holdings Limited Securities Fraud Lawsuit
Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner
More news about: THE ROSEN LAW FIRM, P. A.
Jun 07, 2026, 10:30 ET MimiSilk Marks 12 Years of Advanced Care with New Product Launches and Anniversary Sale
and firm aging skin, delivering professional-level results without the need for in-clinic visits. Unlike conventional RF devices that require conductive gel for treatment, Vera's gel-free technology simplifies the experience without compromising efficacy, making professional-grade
More news about: MimiSilk
Jun 07, 2026, 10:30 ET MimiSilk Marks 12 Years of Advanced Care with New Product Launches and Anniversary Sale
engineered to visibly lift, smooth, and firm aging skin, delivering professional-level results without the need for in-clinic visits. Unlike conventional RF devices that require conductive gel for treatment, Vera's gel-free technology simplifies the experience without compromising efficacy, making professional-grade
More news about: MimiSilk